A randomized controlled trial evaluated the effectiveness of aerobic exercise and sertraline in treating major depressive disorder (MDD). Participants (n=202) were randomly assigned to supervised group exercise, home-based exercise, sertraline, or placebo for 16 weeks. After 4 months, 41% of participants achieved remission (no MDD diagnosis and HAM-D score <8). Active treatments (supervised exercise, home-based exercise, sertraline) had higher remission rates than placebo (45%, 40%, 47% vs. 31%). All treatment groups showed lower HAM-D scores, but no significant difference between active and placebo groups. Exercise was comparable to sertraline in reducing depression, with both outperforming placebo. Placebo response rates were high, suggesting that patient expectations and other non-specific factors contributed to treatment outcomes. Exercise was equally effective as sertraline in reducing depressive symptoms, with both showing better results than placebo. The study found that supervised exercise improved aerobic capacity and treadmill time more than home-based exercise. Exercise and medication were comparable in reducing depressive symptoms, with no significant difference between the two exercise groups. The study highlights the potential of exercise as an effective treatment for MDD, comparable to antidepressants. However, the effect size was modest, and the study was underpowered to detect small differences between exercise conditions. The findings suggest that supervised exercise may yield better outcomes than home-based exercise for physical conditioning, but both are equally effective in achieving remission of clinical depression. The study also notes that the mechanisms behind exercise's antidepressant effects are not fully understood, though psychological and biological factors may contribute. The study underscores the importance of including placebo controls in future research to accurately assess the efficacy of new treatments for MDD.A randomized controlled trial evaluated the effectiveness of aerobic exercise and sertraline in treating major depressive disorder (MDD). Participants (n=202) were randomly assigned to supervised group exercise, home-based exercise, sertraline, or placebo for 16 weeks. After 4 months, 41% of participants achieved remission (no MDD diagnosis and HAM-D score <8). Active treatments (supervised exercise, home-based exercise, sertraline) had higher remission rates than placebo (45%, 40%, 47% vs. 31%). All treatment groups showed lower HAM-D scores, but no significant difference between active and placebo groups. Exercise was comparable to sertraline in reducing depression, with both outperforming placebo. Placebo response rates were high, suggesting that patient expectations and other non-specific factors contributed to treatment outcomes. Exercise was equally effective as sertraline in reducing depressive symptoms, with both showing better results than placebo. The study found that supervised exercise improved aerobic capacity and treadmill time more than home-based exercise. Exercise and medication were comparable in reducing depressive symptoms, with no significant difference between the two exercise groups. The study highlights the potential of exercise as an effective treatment for MDD, comparable to antidepressants. However, the effect size was modest, and the study was underpowered to detect small differences between exercise conditions. The findings suggest that supervised exercise may yield better outcomes than home-based exercise for physical conditioning, but both are equally effective in achieving remission of clinical depression. The study also notes that the mechanisms behind exercise's antidepressant effects are not fully understood, though psychological and biological factors may contribute. The study underscores the importance of including placebo controls in future research to accurately assess the efficacy of new treatments for MDD.